{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:31:44Z","timestamp":1785760304297,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Risdiplam is a validated treatment for adult SMA patients, but clear guidelines concerning functional assessment at baseline and during the follow-up are still limited, especially in terms of sensible and validated outcome measures able to capture minimal changes in motor performances induced by therapy. The aim of this work is to describe the effect of Risdiplam on a cohort of 6 adult type 2 and type 3 SMA patients, using Motor Function Measure (MFM32) as a standardized scaleto quantify the motor improvements induced by therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Risdiplam at the dose of 5\u00a0mg\/daily was administered to a population of 6 (4\u00a0F;2\u00a0M) type 2 (<jats:italic>N<\/jats:italic>\u2009=\u20094) and type 3 (<jats:italic>N<\/jats:italic>\u2009=\u20092), adult SMA patients. Two patients were previously treated by Nusinersen, later suspended due to side effects. At baseline, all patients received a neuromuscular evaluation and a MFM32\u00a0assessment. After the beginning of treatment, we evaluated MFM32, patient reported outcomes (PROs), and adverse events over 7\u201327 months of follow-up. The MFM32 showed an increased score ranging from +\u20092.16% to +\u20097.29% in 4 patients. The improvement was maintained overtime, with two patients presenting the longest follow-up period of 24 and 27 months respectively. Subdomain D3 was ameliorated in 66.6% of patients. Two patients previously treated with Nusinersen maintained the pre-Risdiplam scores. The HFMSE was also performed and failed to show significant improvements after treatment. All patients reported subjective ameliorations. The commonest PROs were improvements in breath fatigue, voice\u2019s intelligibility, hand strength and dexterity. Adverse effects were mild and decreased over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Risdiplam is a well-tolerated treatment in our cohort of adult type 2 and type 3 SMA patients and resulted in improvement or stabilization in motor functions. MFM32 proved to be sensitive to detect changes induced by therapy. Subjective meaningful improvements were sustained overtime especially in bulbar functions, breath fatigue and distal motor abilities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03442-0","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T18:16:12Z","timestamp":1732126572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Risdiplam: therapeutic effects and tolerability in a small cohort of 6 adult type 2 and type 3 SMA patients"],"prefix":"10.1186","volume":"19","author":[{"given":"Gianmarco","family":"Severa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Carmen","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Alimi Ichola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Shoaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Souvannanorath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Jer\u00f4me","family":"Authier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7871-8600","authenticated-orcid":false,"given":"Edoardo","family":"Malfatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"3442_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0140-6736(90)91803-i","volume":"336","author":"J Melki","year":"1990","unstructured":"Melki J, Sheth P, Abdelhak S, Burlet P, Bachelot MF, Lathrop MG, et al. Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. Fr Spinal Muscular Atrophy Investigators Lancet. 1990;336:271\u20133. https:\/\/doi.org\/10.1016\/0140-6736(90)91803-i.","journal-title":"Fr Spinal Muscular Atrophy Investigators Lancet"},{"key":"3442_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71. https:\/\/doi.org\/10.1186\/1750-1172-6-71.","journal-title":"Orphanet J Rare Dis"},{"key":"3442_CR3","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Leary R, McMacken G, K\u00f6nig K, Kirschner J, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264:1465\u201373. https:\/\/doi.org\/10.1007\/s00415-017-8549-1.","journal-title":"J Neurol"},{"key":"3442_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/mus.27519","volume":"65","author":"N Rad","year":"2022","unstructured":"Rad N, Cai H, Weiss MD. Management of spinal muscular atrophy in the Adult Population. Muscle Nerve. 2022;65:498\u2013507. https:\/\/doi.org\/10.1002\/mus.27519.","journal-title":"Muscle Nerve"},{"key":"3442_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/cer-2021-0216","volume":"11","author":"VA Ribero","year":"2022","unstructured":"Ribero VA, Daigl M, Mart\u00ed Y, Gorni K, Evans R, Scott DA, et al. How does Risdiplam compare with other treatments for types 1\u20133 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. J Comp Eff Res. 2022;11:347\u201370. https:\/\/doi.org\/10.2217\/cer-2021-0216.","journal-title":"J Comp Eff Res"},{"key":"3442_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","volume":"8","author":"M Annoussamy","year":"2021","unstructured":"Annoussamy M, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, et al. Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis\u2010SMA study. Ann Clin Transl Neurol. 2021;8:359\u201373. https:\/\/doi.org\/10.1002\/acn3.51281.","journal-title":"Ann Clin Transl Neurol"},{"key":"3442_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13023-023-03008-6","volume":"19","author":"E Salort-Campana","year":"2024","unstructured":"Salort-Campana E, Sol\u00e9 G, Magot A, Tard C, Noury J-B, Behin A, et al. Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments. Orphanet J Rare Dis. 2024;19:24. https:\/\/doi.org\/10.1186\/s13023-023-03008-6.","journal-title":"Orphanet J Rare Dis"},{"key":"3442_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21:42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7.","journal-title":"Lancet Neurol"},{"key":"3442_CR9","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.lanepe.2024.100862","volume":"39","author":"R G\u00fcnther","year":"2024","unstructured":"G\u00fcnther R, Wurster CD, Brakemeier S, Osmanovic A, Schreiber-Katz O, Petri S, et al. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study. Lancet Reg Health Eur. 2024;39:100862. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100862.","journal-title":"Lancet Reg Health Eur"},{"key":"3442_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mus.27804","volume":"67","author":"NC \u00d1ungo Garz\u00f3n","year":"2023","unstructured":"\u00d1ungo Garz\u00f3n NC, Pitarch Castellano I, Sevilla T, V\u00e1zquez-Costa JF. Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy. Muscle Nerve. 2023;67:407\u201311. https:\/\/doi.org\/10.1002\/mus.27804.","journal-title":"Muscle Nerve"},{"key":"3442_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12883-024-03562-x","volume":"24","author":"B Bjelica","year":"2024","unstructured":"Bjelica B, Wohnrade C, Cespedes I, Osmanovic A, Schreiber-Katz O, Petri S. Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction. BMC Neurol. 2024;24:67. https:\/\/doi.org\/10.1186\/s12883-024-03562-x.","journal-title":"BMC Neurol"},{"key":"3442_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/mus.28041","volume":"69","author":"E Milev","year":"2024","unstructured":"Milev E, Selby V, Wolfe A, Rohwer A, Tillmann R, Ramsey D, et al. Assessment of the upper limb function, strength, and mobility in treatment-naive children with spinal muscular atrophy types 2 and 3. Muscle Nerve. 2024;69:340\u20138. https:\/\/doi.org\/10.1002\/mus.28041.","journal-title":"Muscle Nerve"},{"key":"3442_CR13","doi-asserted-by":"publisher","unstructured":"Vuillerot C. State of the art for motor function assessment tools in spinal muscular atrophy (SMA). Arch Pediatr. 2020;27. https:\/\/doi.org\/10.1016\/S0929-693X(20)30276-1. 7S40-47S44.","DOI":"10.1016\/S0929-693X(20)30276-1"},{"key":"3442_CR14","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1111\/ene.14472","volume":"27","author":"B Stolte","year":"2020","unstructured":"Stolte B, Bois J-M, Bolz S, Kizina K, Totzeck A, Schlag M, et al. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy. Eur J Neurol. 2020;27:2586\u201394. https:\/\/doi.org\/10.1111\/ene.14472.","journal-title":"Eur J Neurol"},{"key":"3442_CR15","doi-asserted-by":"publisher","first-page":"2329048X2110087","DOI":"10.1177\/2329048X211008725","volume":"8","author":"K Pierzchlewicz","year":"2021","unstructured":"Pierzchlewicz K, K\u0119pa I, Podogrodzki J, Kotulska K. Spinal muscular atrophy: the Use of Functional Motor scales in the era of Disease-modifying treatment. Child Neurol Open. 2021;8:2329048X211008725. https:\/\/doi.org\/10.1177\/2329048X211008725.","journal-title":"Child Neurol Open"},{"key":"3442_CR16","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui M, Day JW, Deconinck N, Mazzone ES, Nascimento A, Saito K, et al. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023;270:2531\u201346. https:\/\/doi.org\/10.1007\/s00415-023-11560-1.","journal-title":"J Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03442-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03442-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03442-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T19:03:01Z","timestamp":1732129381000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03442-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3442"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03442-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with European Union and French bioethics laws and with the Convention of Helsinki. All patients gave their informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study contains anonymized patient data. No direct patient identifiers have been provided in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Any conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"430"}}